Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis-Reference-Cited by-同舟云学术

Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis

Published:2017-09-06 Issue:2 Volume:4 Page:111-118
ISSN:2055-6837
Container-title:European Heart Journal - Cardiovascular Pharmacotherapy
language:en
Short-container-title:

Author:

Caldeira Daniel¹²,David Cláudio¹²³,Costa João¹²⁴⁵,Ferreira Joaquim J¹²,Pinto Fausto J³

Affiliation:

1. Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Portugal

2. Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Portugal

3. Cardiology Department, Centro Cardiovascular da Universidade de Lisboa (CCUL), Centro Académico Médico de Lisboa (CAML), Faculdade de Medicina, Universidade de Lisboa, Portugal

4. Centro de Estudos de Medicina Baseada na Evidência (CEMBE), Faculdade de Medicina, Universidade de Lisboa, Portugal

5. Portuguese Collaborating Centre of the Cochrane Iberoamerican Network, Faculdade de Medicina, Universidade de Lisboa, Portugal

Funder

FCT

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/ehjcvp/article-pdf/4/2/111/24260541/pvx028.pdf

Reference43 articles.

1. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis;Caldeira;Heart,2014

2. Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis;Caldeira;J Neurol,2015

3. Tolerability and acceptability of non-vitamin K antagonist oral anticoagulants in atrial fibrillation: systematic review and meta-analysis;Caldeira;Am J Cardiovasc Drugs,2015

4. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis;Caldeira;Heart,2015

5. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants;Halvorsen;Eur Heart J Cardiovasc Pharmacother,2017

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-vitamin K versus vitamin K antagonist oral anticoagulants in surgical mitral valve repair or bioprosthetic valve replacement in the first three months after surgery;Revista Portuguesa de Cardiologia;2024-09

2. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS);European Heart Journal;2024-08-30

3. Comparison between non-vitamin K oral antagonist versus warfarin in atrial fibrillation with and without valvular heart disease: a systematic review and meta-analysis;The Egyptian Heart Journal;2024-08-09

4. Direct oral anticoagulants versus vitamin K antagonists: Which one is more effective in atrial fibrillation;Perfusion;2023-09-11

5. Outcomes and Safety of Direct Oral Anticoagulants (DOACs) versus Vitamin K Antagonists (VKAs) amongst Patients with Valvular Heart Disease (VHD): A Systematic Review and Meta-Analysis;Hearts;2023-09-07